News

Articles

FDA has granted Fast Track designation for CUE-101, a treatment of recurrent/metastatic head and neck squamous cell carcinoma. 

FDA Grants Fast Track Designation to Cue Biopharma

Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing. 

PerkinElmer Unveils Cell Analysis Solution

 Washington Editor, jillwechsler7@gmail.com.

FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.

FDA Expands Patient Input on Drug Development 

Biogen has agreed to pay $900 million to settle federal and state claims that it paid kickbacks to physicians to encourage them to prescribe its drugs.

Biogen to Settle Kickbacks Lawsuit for $900 Million

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

Novel Imaging Approach Reveals Key Details About Rare Eye Disease

Actylis combines Aceto and its 10 acquired specialists into a singular global brand.

Actylis Debuts as an Integrated Global Specialty Ingredients Manufacturing and Sourcing Provider

Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.

Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

Legislative leaders are looking to approve a bare-bones measure to fund FDA operations as part of a short-term government funding bill. 

Congress Slated to Reauthorize User Fees Without FDA “Improvements” 

The Public-Private Partnership for Rare Neurodegenerative Diseases will work to enhance understanding and develop treatments for rare neurodegenerative diseases.

Industry News